DONGGUAN, China, March 15, 2016 /PRNewswire/ -- GuangDong Unity Biotechnology Co., Ltd. held a product conference in Xi'an on March 7th, at which the medical equipment manufacturer announced the roll-out and availability of the Automated Glycohemoglobin Analyzer - Abeille, a product that the firm has developed in house. The analyzer, based on a smarter, whole-set design, relies on boric acid affinity chromatography that allows for a significantly shortened testing time. The launch of the analyzer represents a meaningful breakthrough in the Chinese market, which previously dominated by foreign brands including Switzerland's Roche, Japan's Tosoh, the US's Beckman Coulter and Germany's Siemens.
GuangDong Unity specializes in the R&D, production and selling of in vitro diagnostic products (IVD). According to company chairman Lai Hua, the Automated Glycohemoglobin Analyzer - Abeille is an unprecedented combination of features, which can simultaneously detect glycosylated hemoglobin (HbA1c), c-reactive protein (CRP), hypersensitive c-reactive protein (hsCRP), D-Dimer and U - Albumin. Four samples can be processed simultaneously while the test calibration is handled automatically. Test results are provided in 7 seconds as the processing speed has been optimized to reach 50T per hour, a significant time-saver. Abeille is compatible with the LIS system, can automatically store historical data as well as issue alarm for abnormality. Besides, through the 'one-click' operation, the device doesn't require pre-flush and avoid the waste of reagent. Using Abeille in the detection, prevention and control of diabetes can greatly improve efficiency.
Glycosylated hemoglobin is the product of hemoglobin and blood sugar inside human erythrocyte and is proportional to the internal blood sugar concentration of blood glucose in the body. Glycosylated hemoglobin can stably and reliably reflect the average blood glucose level for the 2 to 3 months prior to the test, which is the gold standard to the evaluation of efforts at long-term control of blood sugar levels. As a result, glycosylated hemoglobin detection is both a very simple and a reliable method for the diagnosis of diabetes and is already being used as diagnostics guide in Europe and the United States.
As laboratory equipment in China is expensive and requires regular maintenance, most local healthcare facilities lack the conditon of glycosylated hemoglobin detection capability, limiting the role of primary hospitals in diabetes management. With the rapid increase of diabetes in China and the development of community healthcare, providing glycosylated hemonglobin detection service to a large amout of diabetics in China has become a pressing problem for the country's primary hospitals. Given the circumstances, the launch of GuangDong Unity's Abeille is expected to go a long way in solving this previously intractable problem.
For more information, please visit: http://www.unity-bio.com/
* The above information is provided and confirmed by GuangDong Unity Biotechnology Co., Ltd., issued on behalf of China Technology Media by Guangdong Innovation Technology Media Service Center, reported by Wang Xiangming, Liweiwei
SOURCE Guangdong Innovation Technology Media Service Center